blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2793866

EP2793866 - BILAYER TABLET COMPRISING BENAZEPRIL HYDROCHLORIDE AND PIMOBENDAN [Right-click to bookmark this link]
Former [2014/44]NEW COMBINATION
[2023/28]
StatusPatent maintained as amended
Status updated on  22.09.2023
Database last updated on 11.09.2024
Most recent event   Tooltip12.04.2024Change - lapse in a contracting state
State(s) deleted from list of lapses: GR		published on 15.05.2024  [2024/20]
Applicant(s)For all designated states
Elanco Tiergesundheit AG
Mattenstr. 24A
4058 Basel / CH
[2023/43]
Former [2017/45]For all designated states
Elanco Tiergesundheit AG
Mattenstr. 24A
4058 Basel / CH
Former [2015/13]For all designated states
Novartis Tiergesundheit AG
Werk Rosental
Schwarzwaldallee 215
WRO-1032
4058 Basel / CH
Former [2014/44]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / GRMAS, Jernej
Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
02 / JERALA-STRUKELJ, Zdenka
Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
03 / REVEN, Sebastjan
Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
 [2014/44]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[2023/43]
Former [2015/48]Liphardt, Bernd, et al
Eli Lilly and Company Ltd
European Patent Operations
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey GU20 6PH / GB
Former [2014/44]Liphardt, Bernd
Novartis Animal Health, Inc.
Patent and Trademark Group
Werk Rosenthal
4002 Basel / CH
Application number, filing date12813324.619.12.2012
[2015/48]
WO2012EP76100
Priority number, dateEP2011019501521.12.2011         Original published format: EP 11195015
EP2012018571424.09.2012         Original published format: EP 12185714
[2014/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013092673
Date:27.06.2013
Language:EN
[2013/26]
Type: A2 Application without search report 
No.:EP2793866
Date:29.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 27.06.2013 takes the place of the publication of the European patent application.
[2014/44]
Type: B1 Patent specification 
No.:EP2793866
Date:25.11.2015
Language:EN
[2015/48]
Type: B2 New European patent specification 
No.:EP2793866
Date:25.10.2023
Language:EN
[2023/43]
Search report(s)International search report - published on:EP12.09.2013
ClassificationIPC:A61K9/20, A61K31/4184, A61K31/501, A61K47/12
[2014/44]
CPC:
A61K9/209 (EP,US); A61K31/501 (EP,US); A61K31/55 (EP,US);
A61K9/1676 (EP,US); A61K9/5073 (US); A61P43/00 (EP);
A61P9/04 (EP); A61P9/12 (EP); A61K9/1652 (EP,US);
A61K9/5026 (EP,US); A61K9/5078 (EP,US) (-)
C-Set:
A61K31/501, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/44]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZWEISCHICHTTABELLE ENTHALTEND BENAZEPRILHYDROCHLORID UND PIMOBENDAN[2023/28]
English:BILAYER TABLET COMPRISING BENAZEPRIL HYDROCHLORIDE AND PIMOBENDAN[2023/28]
French:COMPRIMÉ BICOUCHE COMPRENANT DU CHLORHYDRATE DE BÉNAZÉPRIL ET DU PIMOBENDANE[2023/28]
Former [2014/44]NEUE KOMBINATION
Former [2014/44]NEW COMBINATION
Former [2014/44]NOUVELLE COMBINAISON
Entry into regional phase21.07.2014National basic fee paid 
21.07.2014Designation fee(s) paid 
21.07.2014Examination fee paid 
Examination procedure21.07.2014Examination requested  [2014/44]
23.01.2015Amendment by applicant (claims and/or description)
01.07.2015Communication of intention to grant the patent
06.10.2015Fee for grant paid
06.10.2015Fee for publishing/printing paid
06.10.2015Receipt of the translation of the claim(s)
Divisional application(s)EP15193269.6  / EP3034071
EP17199031.0  / EP3320894
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.07.2015
Opposition(s)Opponent(s)01  23.08.2016  29.08.2016  ADMISSIBLE
Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Opponent's representative
Banse & Steglich Patentanwälte PartmbB, et al, et al
Patentanwaltskanzlei
Herzog-Heinrich-Straße 23
80336 München / DE
 [2019/52]
Former [2017/18]
Opponent(s)01  23.08.2016  29.08.2016  ADMISSIBLE
Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Opponent's representative
Banse & Steglich, et al, et al
Patentanwaltskanzlei
Herzog-Heinrich-Straße 23
80336 München / DE
Former [2016/40]
Opponent(s)01  23.08.2016  29.08.2016  ADMISSIBLE
Boehringer Ingelheim Vetmedica GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
Opponent's representative
Simon, Elke Anna Maria, et al, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
30.09.2016Invitation to proprietor to file observations on the notice of opposition
30.01.2017Reply of patent proprietor to notice(s) of opposition
15.12.2017Date of oral proceedings
08.03.2018Despatch of minutes of oral proceedings
03.05.2022Despatch of a communication from the opposition division (Time limit: M02)
06.05.2022Reply to a communication from the opposition division
23.02.2023Despatch of interlocutory decision in opposition
05.03.2023Legal effect of interlocutory decision in opposition
15.06.2023Despatch of communication that the patent will be maintained as amended
13.09.2023Fee for printing new specification paid
Appeal following opposition03.05.2018Appeal received No.  T1131/18
16.07.2018Statement of grounds filed
19.10.2021Result of appeal procedure: maintenance in amended form
07.02.2022Despatch of the decision of the Board of Appeal
19.10.2021Date of oral proceedings
Fees paidRenewal fee
11.12.2014Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipSM25.11.2015
AL19.12.2019
CY19.12.2019
FI19.12.2019
HR19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
MT19.12.2019
RO19.12.2019
RS19.12.2019
SK19.12.2019
SI20.12.2019
EE31.12.2019
IS01.01.2020
MC02.01.2020
BG30.06.2020
[2024/20]
Former [2022/07]SM25.11.2015
AL19.12.2019
CY19.12.2019
FI19.12.2019
HR19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
MT19.12.2019
RO19.12.2019
RS19.12.2019
SK19.12.2019
SI20.12.2019
EE31.12.2019
IS01.01.2020
MC02.01.2020
BG30.06.2020
GR07.07.2020
Former [2021/31]SM25.11.2015
CY19.12.2019
FI19.12.2019
HR19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
RO19.12.2019
RS19.12.2019
SK19.12.2019
SI20.12.2019
EE31.12.2019
IS01.01.2020
MC02.01.2020
BG30.06.2020
GR07.07.2020
Former [2021/01]SM25.11.2015
CY19.12.2019
FI19.12.2019
HR19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
RO19.12.2019
RS19.12.2019
SK19.12.2019
SI20.12.2019
EE31.12.2019
MC02.01.2020
BG30.06.2020
GR07.07.2020
Former [2020/51]SM25.11.2015
CY19.12.2019
FI19.12.2019
HR19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
RO19.12.2019
RS19.12.2019
SK19.12.2019
SI20.12.2019
EE31.12.2019
MC02.01.2020
GR07.07.2020
Former [2020/50]SM25.11.2015
CY19.12.2019
FI19.12.2019
HR19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
RO19.12.2019
SK19.12.2019
SI20.12.2019
EE31.12.2019
MC02.01.2020
GR07.07.2020
Former [2020/47]SM25.11.2015
CY19.12.2019
FI19.12.2019
LT19.12.2019
LU19.12.2019
LV19.12.2019
RO19.12.2019
MC02.01.2020
Former [2020/46]SM25.11.2015
CY19.12.2019
FI19.12.2019
LU19.12.2019
LV19.12.2019
RO19.12.2019
MC02.01.2020
Former [2020/39]SM25.11.2015
CY19.12.2019
FI19.12.2019
LV19.12.2019
RO19.12.2019
MC02.01.2020
Former [2020/38]SM25.11.2015
CY19.12.2019
FI19.12.2019
LV19.12.2019
RO19.12.2019
Former [2020/35]SM25.11.2015
CY19.12.2019
FI19.12.2019
RO19.12.2019
Former [2017/11]SM25.11.2015
Former [2016/49]SM25.11.2015
BG30.09.2016
Former [2016/38]SM25.11.2015
Former [2016/27]deleted
Former [2016/25]LV25.11.2015
Cited inInternational search[Y]WO03075895  (NOVARTIS AG [CH], et al);
 [Y]US2005203097  (FOLGER MARTIN A [DE], et al);
 [Y]US2010035889  (DAEMMGEN JUERGEN [DE], et al);
 [Y]US2010183718  (OVAERT PATRICIA [FR], et al);
 [Y]WO2011111066  (CONNEXIOS LIFE SCIENCES PVT LTD [IN], et al);
by applicantEP1490037
 WO2010055119
OppositionUS6162802
 JP2005281283
 WO2006085208
 EP1490037
 WO2008095263
 WO2010097501
 WO2011111066
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.